Poland· PL-100030400
Immunofort
A medicinal product containing preparat ziołowy, registered in Poland by Przedsiębiorstwo Farmaceutyczne "Leki Natury" Tadeusz Polański Sp. z o.o..
Checked against URPL (Poland) on
Informational only — not a medical device.
The record
At a glance
URPL (Poland)- Active substance
- Preparat ziołowy
- Manufacturer
- Przedsiębiorstwo Farmaceutyczne "Leki Natury" Tadeusz Polański Sp. z o.o.
- Country
- Poland (PL)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05909990159918
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/163753f3-b5a3-4eb6-b0a3-82b476ef89ab GET /v1/drugs/163753f3-b5a3-4eb6-b0a3-82b476ef89ab?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Płyn doustny",
"source": "urpl",
"strength": "-",
"packaging": "05909990159918 ¦ OTC ¦ 4847\n1 butelka 125 g\nOTC ¦ Skasowane ¦ 4848\n1 fl. 150 g\nOTC ¦ Skasowane ¦ 4849\n1 fl. 200 g",
"substance": "Echinaceae succus stabilisatus (1:1) 40 g + Aroniae fructus succus (1:1) 30 g + Urticae herbae recentis succus (1:1) 10 g + Bardanae radicis recentis succus (1:1) 10 g + Matricariae floris extractum fluidum (0,5: 1) 10 g",
"common_name": "Preparat ziołowy",
"pl_product_id": "100030400",
"pozwolenie_nr": "01599",
"auth_procedure": "NAR",
"authorisation_validity": "Bezterminowe"
}See everything about preparat ziołowy.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.